Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (131-140 of 234) with videos related to

Pageof 24
Sort By:
Anti-Cancer Drugs|August 21, 2002
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxelWalter J Loos, Janos Szebeni, Albert J ten Tije, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area valuesWalter J Loos, Felix E de Jongh, Alex Sparreboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic studyFrederike K Engels, Walter J Loos, Jessica M van der Bol, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2009
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Stefan Sleijfer, Monia Ouali, Martine van Glabbeke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Comparative pharmacokinetics of weekly and every-three-weeks docetaxelSharyn D Baker, Ming Zhao, Carlton K K Lee, et al.
Investigational New Drugs|October 12, 2012
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumorsMaja J A de Jonge, Paul Hamberg, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studiesAlex Sparreboom, Antonio C Wolff, Jaap Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 2014
The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastasesGaia Schiavon, Alessandro Ruggiero, Dave J Bekers, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 4, 2014
Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitmentTrudy Straetemans, Cor Berrevoets, Miriam Coccoris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecanWalter J Loos, Jaap Verweij, Diederik F S Kehrer, et al.
Pageof 24

Showing results (131-140 of 234) with videos related to

Sort By:
Pageof 24
Anti-Cancer Drugs|August 21, 2002
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxelWalter J Loos, Janos Szebeni, Albert J ten Tije, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area valuesWalter J Loos, Felix E de Jongh, Alex Sparreboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic studyFrederike K Engels, Walter J Loos, Jessica M van der Bol, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2009
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Stefan Sleijfer, Monia Ouali, Martine van Glabbeke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Comparative pharmacokinetics of weekly and every-three-weeks docetaxelSharyn D Baker, Ming Zhao, Carlton K K Lee, et al.
Investigational New Drugs|October 12, 2012
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumorsMaja J A de Jonge, Paul Hamberg, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studiesAlex Sparreboom, Antonio C Wolff, Jaap Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 2014
The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastasesGaia Schiavon, Alessandro Ruggiero, Dave J Bekers, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 4, 2014
Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitmentTrudy Straetemans, Cor Berrevoets, Miriam Coccoris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecanWalter J Loos, Jaap Verweij, Diederik F S Kehrer, et al.
Pageof 24